Decoy Therapeutics Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing captures Decoy Therapeutics at a critical inflection point, balancing a high-upside technological pivot against a deteriorating liquidity profile. The merger with Legacy Decoy has successfully consolidated the IMP3ACT platform, but the transition has accelerated cash burn and left the company with a narrow window to achieve a value-unlocking event. The shift in R&D spending confirms that management is all-in on the AI-peptide strategy, effectively abandoning previous clinical paths in favor of the D-MAV program. For investors, the trade-off is now stark: the potential for a paradigm shift in peptide conjugate discovery versus the very real risk of insolvency or extreme dilution. The company's ability to maintain its Nasdaq listing and secure additional non-dilutive funding will be the primary indicators of survival. The upcoming window for IND filings in 2027 represents the ultimate catalyst, but the path there requires a level of financial stability that is not currently evident in the unaudited balance sheet.